Patient ID | Serum PSA (ng/L) | Gleason grade group | pTN stage | Fresh frozen samples sequenced# | Length of follow-up | Current clinical statusa | Main genomic findings |
---|---|---|---|---|---|---|---|
#02 | 36.8 | 5 | 3bN1 | P 8 SV 1  + FFPE samples: LN 3 | 3 years | PPP. Nodal and bone metastases. On ADT + chemotherapy (Docetaxel) | Branching evolution in the prostate. Evolution driven primarily by SNVs; polyclonal SV sample |
#08 | 6.50 | 5 | 3bN1 | P 6 SV 2 | 3 years | PPP. Residual pelvic lymph node disease. On ADT + chemotherapy (Docetaxel) | Branching evolution in the prostate. Evolution driven by a number of CNAs in addition to SNVs; FOXP1 deletion in clone spreading to SV; polyclonal SV |
#10 | 5.08 | 3 (with amphicrine differentiation) | 3bN1 | P 5 LN 4 SV 0  + FFPE samples: P 3 SV 1 | 3 years | PPP. Widespread lymph node metastases on CT. On ADT + chemotherapy (Cisplatin/Etoposide) | Branching evolution in the prostate. Amphicrine prostate cancer evolved from Adenocarcinoma; |
#13 | 46.30 | 3 | 3bN1 | P 5 LN 1 | 3 years | Recurrent pelvic lymph node and bone metastases. On ADT + chemotherapy (Docetaxel) | Branching evolution in the prostate. No notable histological heterogeneity |
#15 | 6.83 | 5 | 3aN1 | P 2 LN 2 | 3Â years | Salvage pelvic radiotherapy for rising PSA to 0.29. PSMA-PET negative | Branching evolution in the prostate. Whole genome doubling; chromoplexy; increased SBS3 |